1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,430 | 1,495 | 23:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.01. | Aelis Farma Announces Its 2026 Financial Calendar | 177 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral... ► Artikel lesen | |
| 12.01. | Aelis Farma Receives a Positive Opinion From EMA Pediatric Committee on the Pediatric Investigation Plan for AEF0217 in Down Syndrome | 219 | Business Wire | The EMA's Pediatric Committee (PDCO) has delivered a favorable consensus opinion on the Pediatric Investigational Plan (PIP) of Aelis Farma's first-in-class drug candidate AEF0217 for the treatment... ► Artikel lesen | |
| 02.12.25 | Aelis Farma Obtains Regulatory Approval of the Phase 2B Trial With AEF0217 in People With Down Syndrome | 366 | Business Wire | AEF0217 is a first-in-class CB1 receptor Signalling Specific inhibitor (CB1-SSi) developed as a potential first pharmacological treatment for impairments in adaptive behaviours and cognition... ► Artikel lesen | |
| 25.09.25 | Aelis Farma: Availability of the 2025 Half-Year Financial Report | 313 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 22.09.25 | Aelis Farma Reports 2025 Half-Year Financial Results and Presents Progress and Development Outlook | 484 | Business Wire | The first half of 2025 was marked by: The publication of the final analysis of the pioneering Phase 2b clinical trial in cannabis use disorders (CUD) with the CB1-SSi AEF0117, which further... ► Artikel lesen | |
| 24.06.25 | Aelis Farma: Availability of the Description of the Share Buyback Program | 389 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| AELIS FARMA Aktie jetzt für 0€ handeln | |||||
| 27.05.25 | Results of Aelis Farma Combined General Meeting of May 27, 2025 | 417 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 06.05.25 | Aelis Farma: Combined General Meeting of May 27, 2025: Availability of Preparatory Documents and Participation and Voting Procedures | 420 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 29.04.25 | Aelis Farma: Availability of the 2024 Universal Registration Document | 340 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 01.04.25 | Aelis Farma Reports Its 2024 Annual Financial Results and Confirms Its 2025 Outlook | 534 | Business Wire | 2024 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates:
AEF0117: announcement of the results of the Phase 2b clinical... ► Artikel lesen | |
| 26.03.25 | Aelis Farma Announces the Final Analysis of the Landmark Phase 2B Clinical Trial in Cannabis Use Disorder (CUD) with the CB1-SSi AEF0117 | 554 | Business Wire | The purpose of this pioneering Phase 2B trial was to show that AEF0117 reduces cannabis use and to determine the endpoints and optimal dosage to be used in future studies. AEF0117 is the first... ► Artikel lesen | |
| 17.02.25 | Aelis Farma Announces Its 2025 Financial Calendar | 372 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 77,70 | +0,69 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,900 | -4,99 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 81,26 | -3,09 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| AVIDITY BIOSCIENCES | 72,72 | -0,29 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 36,850 | -1,21 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,440 | +33,33 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| OLEMA PHARMACEUTICALS | 26,340 | +0,77 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| QIAGEN | 43,845 | -0,43 % | QIAGEN N.V.: QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026 | QIAsprint Connect marks entry into high-throughput sample processing, enabling labs to scale workflows with flexible protocols, compact design and sustainability-focused features QIAGEN... ► Artikel lesen | |
| ALUMIS | 26,350 | -2,62 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TARSUS PHARMACEUTICALS | 63,51 | -4,93 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| BIONTECH | 92,50 | +1,09 % | BioNTech ernennt Kylie Jimenez zur Chief People Officer | Der Aufsichtsrat der BioNTech SE hat Kylie Jimenez mit Wirkung zum 1. März 2026 zur neuen Chief People Officer (Chief People Officer) ernannt. Die neu geschaffene Vorstandsposition umfasst die Verantwortung... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,910 | -0,29 % | MEDICAL BioHealth Fonds: Eli Lilly kauft Ventyx Biosciences | Gräfelfing (www.fondscheck.de) - Anbei eine aktuelle Pressemitteilung der Medical Strategy GmbH:Zum Kauf von Ventyx Biosciences durch Eli Lilly ein Statement von Mario Linimeier, Geschäftsführer der... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 303,34 | -2,15 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| SUMMIT THERAPEUTICS | 14,430 | -1,10 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock |
Das Unternehmen AELIS FARMA SAS kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +13,48 % bei einem Aktienkurs von 1,515 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AELIS FARMA SAS finden Sie auf Wallstreet Online.